EGFR-IN-173

EGFR-IN-173 is an orally active, broad-spectrum mutant EGFR tyrosine kinase inhibitor that targets EGFR19del, L858R/T790M, and the triple mutation C797S, with an IC50 of 1.19 nM, effectively inhibiting the EGFR19del/T790M/C797S mutant. It demonstrates over 100-fold selectivity for mutated EGFR compared to the wild type [wild type IC50= 19.362 μM]. EGFR-IN-173 significantly suppresses cell migration, induces apoptosis in non-small cell lung cancer (NSCLC) cells, inhibits EGFR phosphorylation, and blocks downstream pathways (MAPK/ERK, AKT, STAT3) . It shows antitumor activity in NSCLC and Ba/F3 xenograft models and is applicable in NSCLC research.